Table 2 Relation between pre-infusion albumin level and commonly observed toxicities of the HDMTX cycles (N = 120)
Pre-infusion Albumin (g/dL) | p | ||
|---|---|---|---|
<3.5 g/dL (N = 38) | ≥3.5 g/dL (N = 82) | ||
N (%) | |||
Hematological toxicities | |||
Neutropenia | |||
No | 8 (21.1) | 20 (24.4) | “χ2 test” p=0.688 |
Yes | 30 (78.9) | 62 (75.6) | |
G3–4 | 24 (63.2) | 46 (56.1) | “χ2 test” p=0.466 |
Anemia | |||
No | 4 (10.5) | 24 (29.3) | “χ2 test” p=0.024 |
Yes | 34 (89.5) | 58 (70.7) | |
G3-4 | 18 (47.4) | 17 (20.7) | “χ2 test” p=0.003 |
Thrombocytopenia | |||
No | 20 (52.6%) | 63 (76.8%) | “χ2 test” p=0.008 |
Yes | 18 (47.4%) | 19 (23.2%) | |
G3–4 | 11 (28.9) | 8 (9.8) | “χ2 test” p=0.007 |
Febrile neutropeniaa | |||
No | 22 (57.9) | 67 (81.7) | “χ2 test” p=0.006 |
Yes | 16 (42.1) | 15 (18.3) | |
Hepatic toxicity | |||
Increased ALT | |||
No | 26 (68.4) | 60 (73.2) | “χ2 test” p=0.591 |
Yes | 12 (31.6) | 22 (26.8) | |
G3–4 | 1 (2.6%) | 5 (6.1%) | FEp=0.663 |
Increased AST | |||
No | 24 (63.2) | 63 (76.8) | “χ2 test” p=0.119 |
Yes | 14 (36.8) | 19 (23.2) | |
G3–4 | 2 (5.3%) | 2 (2.4%) | FEp=0.590 |
Gastrointestinal toxicity | |||
Oral mucositis | |||
No | 16 (42.1) | 60 (73.2) | “χ2 test” p=0.001 |
Yes | 22 (57.9) | 22 (26.8) | |
G3–4 | 9 (23.7%) | 11 (13.4%) | “χ2 test” p=0.160 |
Nephrotoxicity | |||
Increased creatinine | |||
No | 22 (57.9) | 58 (70.7) | “χ2 test” p=0.165 |
Yes | 16 (42.1) | 24 (29.3) | |
G3–4 | 0 (0%) | 2 (2.4%) | FEp=1.000 |
Hospitalizationb | |||
No | 23 (60.5) | 65 (79.3) | “χ2 test” p=0.031 |
Yes | 15 (39.5) | 17 (20.7) | |
Length of hospitalization | (N = 15) | (N = 17) | |
Median (IQR) | 4 (3–8) | 6 (3.5–7.5) | “U test” p=0.576 |
Min.–Max. | 2–14 | 2–12 | |